CA3109983A1 - Spd-1 variant - fc fusion proteins - Google Patents
Spd-1 variant - fc fusion proteins Download PDFInfo
- Publication number
- CA3109983A1 CA3109983A1 CA3109983A CA3109983A CA3109983A1 CA 3109983 A1 CA3109983 A1 CA 3109983A1 CA 3109983 A CA3109983 A CA 3109983A CA 3109983 A CA3109983 A CA 3109983A CA 3109983 A1 CA3109983 A1 CA 3109983A1
- Authority
- CA
- Canada
- Prior art keywords
- spd
- variant
- domain
- seq
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731488P | 2018-09-14 | 2018-09-14 | |
| US62/731,488 | 2018-09-14 | ||
| US201962888320P | 2019-08-16 | 2019-08-16 | |
| US62/888,320 | 2019-08-16 | ||
| PCT/US2019/050742 WO2020056085A1 (en) | 2018-09-14 | 2019-09-12 | Spd-1 variant - fc fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3109983A1 true CA3109983A1 (en) | 2020-03-19 |
Family
ID=68211179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3109983A Pending CA3109983A1 (en) | 2018-09-14 | 2019-09-12 | Spd-1 variant - fc fusion proteins |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11498955B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3850003A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021535761A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210058902A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112969710A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019338416A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3109983A1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ774126A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202101904UA (cg-RX-API-DMAC7.html) |
| TW (2) | TW202348622A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020056085A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016164428A1 (en) * | 2015-04-06 | 2016-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway |
| EP3991741A1 (en) * | 2020-11-02 | 2022-05-04 | Klinikum rechts der Isar der Technischen Universität München | An immune checkpoint-modulating vsv-ndv hybrid virus for oncolytic virus immonotherapy of cancer |
| US20230414660A1 (en) * | 2020-11-13 | 2023-12-28 | Ludwig Institute For Cancer Research Ltd | Pd-1 decoy variants for immunotherapy |
| WO2022137186A1 (en) | 2020-12-23 | 2022-06-30 | Crispr Therapeutics Ag | Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor |
| CN117321079A (zh) * | 2021-01-11 | 2023-12-29 | 优特力克斯有限公司 | 包含抗4-1bb抗体及pd-1蛋白或其片段的双特异性表位结合蛋白及其用途 |
| EP4288080A1 (en) * | 2021-02-04 | 2023-12-13 | Helsingin Yliopisto | A cross-hybrid fc-fusion polypeptide targeting pd-l1 and methods and uses related thereto |
| WO2022187488A2 (en) * | 2021-03-03 | 2022-09-09 | Shattuck Labs, Inc. | Mutant pd-1 extracellular domains |
| US20220387488A1 (en) | 2021-05-12 | 2022-12-08 | Crispr Therapeutics Ag | Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies |
| EP4346875A4 (en) * | 2021-05-28 | 2025-04-16 | Akso Biopharmaceutical, Inc. | BISPECIFIC FC FUSION PROTEINS WITH SPD-1 AND IL-15 |
| KR20230044131A (ko) * | 2021-09-24 | 2023-04-03 | 바이오엔시스템스 주식회사 | Pd-1 및 il-15를 포함하는 융합단백질 이량체 및 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110034373A1 (en) * | 2007-08-03 | 2011-02-10 | Eli Lilly And Company | Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity |
| CN103261217B (zh) * | 2010-11-11 | 2017-04-26 | 港大科桥有限公司 | 可溶性 pd‑1变体、融合构建体及其用途 |
| US20150368316A1 (en) * | 2013-02-07 | 2015-12-24 | Albert Einstein College Of Medicine Of Yeshiva University | A selective high-affinity immune stimulatory reagent and uses thereof |
| WO2016023001A1 (en) | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| EP3177640B1 (en) * | 2014-08-08 | 2020-05-06 | The Board of Trustees of the Leland Stanford Junior University | High affinity pd-1 agents and methods of use |
| WO2016164428A1 (en) * | 2015-04-06 | 2016-10-13 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway |
| US10844392B2 (en) * | 2015-06-05 | 2020-11-24 | Ibio, Inc. | Materials and methods for producing endostatin fusion polypeptides in plant cells |
| PL3368572T5 (pl) * | 2015-10-02 | 2026-07-20 | Les Laboratoires Servier | Przeciwciała anty-PD-1 oraz kompozycje |
| WO2017123548A1 (en) | 2016-01-14 | 2017-07-20 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment |
| WO2018104473A1 (en) * | 2016-12-07 | 2018-06-14 | Oslo Universitetssykehus Hf | Compositions and methods for cell therapy |
| WO2019241758A1 (en) * | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
-
2019
- 2019-09-12 KR KR1020217010801A patent/KR20210058902A/ko not_active Ceased
- 2019-09-12 US US16/569,105 patent/US11498955B2/en active Active
- 2019-09-12 JP JP2021539337A patent/JP2021535761A/ja active Pending
- 2019-09-12 CA CA3109983A patent/CA3109983A1/en active Pending
- 2019-09-12 CN CN201980060042.5A patent/CN112969710A/zh active Pending
- 2019-09-12 TW TW112132395A patent/TW202348622A/zh unknown
- 2019-09-12 EP EP19786693.2A patent/EP3850003A1/en not_active Withdrawn
- 2019-09-12 WO PCT/US2019/050742 patent/WO2020056085A1/en not_active Ceased
- 2019-09-12 AU AU2019338416A patent/AU2019338416A1/en not_active Abandoned
- 2019-09-12 NZ NZ774126A patent/NZ774126A/en not_active IP Right Cessation
- 2019-09-12 TW TW108133070A patent/TWI815964B/zh not_active IP Right Cessation
- 2019-09-12 SG SG11202101904UA patent/SG11202101904UA/en unknown
-
2022
- 2022-10-10 US US17/962,983 patent/US20230131056A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020056085A1 (en) | 2020-03-19 |
| EP3850003A1 (en) | 2021-07-21 |
| US20230131056A1 (en) | 2023-04-27 |
| TW202348622A (zh) | 2023-12-16 |
| NZ774126A (en) | 2023-05-26 |
| AU2019338416A1 (en) | 2021-04-29 |
| KR20210058902A (ko) | 2021-05-24 |
| US11498955B2 (en) | 2022-11-15 |
| US20200181231A1 (en) | 2020-06-11 |
| CN112969710A (zh) | 2021-06-15 |
| JP2021535761A (ja) | 2021-12-23 |
| SG11202101904UA (en) | 2021-04-29 |
| TWI815964B (zh) | 2023-09-21 |
| TW202023604A (zh) | 2020-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230131056A1 (en) | sPD-1 VARIANT – FC FUSION PROTEINS | |
| US20230055445A1 (en) | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof | |
| JP7273453B2 (ja) | IL-15/IL-15RアルファFc融合タンパク質およびPD-1抗体の断片を含む二重特異性ヘテロ二量体融合タンパク質 | |
| JP7809680B2 (ja) | 癌処置のための多重特異性結合タンパク質 | |
| JP2024153643A (ja) | Il-15/il-15raヘテロ二量体fc融合タンパク質およびその使用 | |
| CN107614013B (zh) | 结合lag-3的分子和其使用方法 | |
| KR20210010862A (ko) | IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도 | |
| US20250215081A1 (en) | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies | |
| US12275798B2 (en) | Tri-specific binding molecules | |
| RU2785993C2 (ru) | ГИБРИДНЫЕ БЕЛКИ ВАРИАНТА sPD-1—FC | |
| CN117715940A (zh) | 抗trem-1抗体 | |
| NZ796397A (en) | sPD-1 variant - Fc fusion proteins | |
| CN114867751A (zh) | 4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体 | |
| HK40053326A (en) | Spd-1 variant - fc fusion proteins | |
| RU2827796C2 (ru) | Гетеродимерные слитые белки ИЛ-15/ИЛ-15Рα - Fc и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220926 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20240807 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240822 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250110 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260106 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260109 |